<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Dove Medical Press Ltd.</publisher>
				<availability status="unknown"><p>Copyright Dove Medical Press Ltd.</p>
				</availability>
				<date type="published" when="2017-03">2017-03</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Liu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of gastroenterology</orgName>
								<orgName type="institution">Weifang People&apos;s hospital</orgName>
								<address>
									<settlement>Weifang</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying</forename><surname>Mu</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of gastroenterology</orgName>
								<orgName type="institution">liaocheng People&apos;s hospital</orgName>
								<address>
									<addrLine>3 central laboratory</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">liaocheng clinical school of Taishan Medical University</orgName>
								<address>
									<settlement>liaocheng, shandong Province</settlement>
									<country>People&apos;s republic of china</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anqi</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shaoda</forename><surname>Ren</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weihua</forename><surname>Wang</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiaping</forename><surname>Xie</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of gastroenterology</orgName>
								<orgName type="institution">liaocheng People&apos;s hospital</orgName>
								<address>
									<addrLine>3 central laboratory</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">liaocheng clinical school of Taishan Medical University</orgName>
								<address>
									<settlement>liaocheng, shandong Province</settlement>
									<country>People&apos;s republic of china</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yingxin</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Changhui</forename><surname>Zhou</surname></persName>
						</author>
						<title level="a" type="main">Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis</title>
					</analytic>
					<monogr>
						<title level="j" type="main">OncoTargets and Therapy</title>
						<title level="j" type="abbrev">OTT</title>
						<idno type="eISSN">1178-6930</idno>
						<imprint>
							<publisher>Dove Medical Press Ltd.</publisher>
							<biblScope unit="volume">Volume10</biblScope>
							<biblScope unit="page" from="1897" to="1908"/>
							<date type="published" when="2017-03" />
						</imprint>
					</monogr>
					<idno type="DOI">10.2147/ott.s132507</idno>
					<idno type="PMID">28408841</idno>
					<idno type="PMCID">PMC5384723</idno>
					<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=35737" />
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:30+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>cytokine-induced killer cells</term>
					<term>dendritic cells</term>
					<term>esophageal cancer</term>
					<term>immunotherapy</term>
					<term>meta-analysis</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: Immunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies. Therefore, it is necessary to systematically evaluate the curative efficacy and safety of CIK/ DC-CIK immunotherapy as an adjuvant therapy for conventional therapeutic strategies in the treatment of EC. Materials and methods: Clinical trials published before October 2016 and reporting CIK/ DC-CIK immunotherapy treatment responses or safety for EC were searched in Cochrane Library, EMBASE, PubMed, Wanfang and China National Knowledge Internet databases. Research quality and heterogeneity were evaluated before analysis, and pooled analyses were performed using random-or fixed-effect models. Results: This research covered 11 trials including 994 EC patients. Results of this metaanalysis indicated that compared with conventional therapy, the combination of conventional therapy with CIK/DC-CIK immunotherapy significantly prolonged the 1-year overall survival (OS) rate, overall response rate (ORR) and disease control rate (DCR) (1-year OS: P=0.0005; ORR and DCR: P,0.00001). Patients with combination therapy also showed significantly improved quality of life (QoL) (P=0.02). After CIK/DC-CIK immunotherapy, lymphocyte percentages of CD3 + and CD3-CD56 + subsets (P,0.01) and cytokines levels of IFN-γ,-2, TNF-α and IL-12 (P,0.00001) were significantly increased, and the percentage of cluster of differentiation (CD)4 + CD25 + CD127subset was significantly decreased, whereas analysis of CD4 + , CD8 + , CD4 + /CD8 + and CD3 + CD56 + did not show significant difference (P.0.05). Conclusion: The combination of CIK/DC-CIK immunotherapy and conventional therapy is safe and markedly prolongs survival time, enhances immune function and improves the treatment efficacy for EC.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Esophageal cancer (EC) is a global common cancer, with 450,000 new cases and 400,000 estimated deaths per year. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> The incidence of EC has increased exponentially over the past few decades and the 5-year survival rate remains bleak. <ref type="bibr" target="#b2">3</ref> At present, surgery, radiotherapy and chemotherapy are most widely used for EC. <ref type="bibr" target="#b3">4</ref>  application is limited by the failure to thoroughly eliminate tumor cells, drug resistance and other adverse effects. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref> Therefore, a more effective and safer therapeutic method is urgently required.</p><p>In recent years, immunotherapy has been rising rapidly and is considered the fourth powerful therapeutic method after surgery, radiotherapy and chemotherapy. <ref type="bibr" target="#b5">6</ref> Cancer immunotherapy is accomplished in multiple ways, including manipulation of the immune system through the use of immune agents, such as vaccines, <ref type="bibr" target="#b6">7</ref> cytokines, <ref type="bibr" target="#b7">8</ref> checkpoint inhibitors (including anti-programmed death 1 [PD-1]/PD-ligand 1 [PD-L1] antibodies and anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 antibodies), <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref> kinase inhibitors (such as apatinib and gefitinib) <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref> and immune cells. <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref><ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref> However, their applications have the following hurdles. Simply activating the immunity via vaccination is not able to thoroughly eliminate tumor cells because cancer patients are usually in immunosuppression. <ref type="bibr" target="#b19">19</ref> Promotion of molecule-targeted treatment for tumors is also confined only to cancer patients bearing specific antigenexpressing cells. <ref type="bibr" target="#b12">13</ref> Notably, adoptive cellular immunotherapy has been flourishing in cancer treatment. Its effectiveness relies on the application of dendritic cells (DCs), <ref type="bibr" target="#b13">14</ref> tumorinfiltrating lymphocytes (TILs), <ref type="bibr" target="#b14">15</ref> natural killer (NK) cells, <ref type="bibr" target="#b16">16</ref> cytotoxic T lymphocytes (CTLs), <ref type="bibr" target="#b17">17</ref> cytokine-induced killer (CIK) cells <ref type="bibr" target="#b18">18</ref> and other immune cells. CIK cells, which consist primarily of the CD3 + CD56 + subset, are induced by interferon (IFN)-γ, interleukin (IL)-1, cluster of differentiation (CD)3 monoclonal antibodies (OKT3) and IL-2 in vitro. <ref type="bibr" target="#b4">5</ref> Compared with other immune cells, CIK cells are easy to obtain from peripheral blood and umbilical cord blood mononuclear cells, and they possess higher in vitro proliferation capacity, stronger antitumor activity and broader antitumor spectrum. <ref type="bibr" target="#b5">6</ref> The tumoricidal ability of CIK cells is implemented by inducing tumor cell apoptosis through direct contact and secretion of cytokines such as IL-2, tumor necrosis factor (TNF)-α and IFN-γ. <ref type="bibr" target="#b20">20</ref> CIK cells have shown promising prospects in immunotherapy for cancers. On the one hand, the cytotoxicity of CIK cells is not affected by immune inhibitors such as cyclosporin A (CsA) and FK506. <ref type="bibr" target="#b21">21</ref> On the other hand, CIK cell-mediated cytotoxicity does not rely on the major histocompatibility complex (MHC). As in most cancers, these cells do not express MHC or human leukocyte antigen (HLA); this property of CIK cells is a great advantage over other immune cells in adoptive cell therapy. <ref type="bibr" target="#b22">22</ref> DCs are the most potent antigen-presenting cells and are essential in CIK activation, proliferation, phenotype expression and cytokine secretion. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b23">23,</ref><ref type="bibr" target="#b24">24</ref> The cytotoxicity of CIK cells is remarkably enhanced when cocultured with DCs, indicated by the increased proportion of CD3 + CD56 + cells and the improved levels of cytokines such as IL-2, IFN-γ, IL-12 and TNF-α. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b23">23</ref> Meanwhile, cocultured DCs also downregulate the expression of negative regulatory factors, including transforming growth factor (TGF)-β and IL-10, as well as the proportion of CD4 + CD25 + regulatory T cells (Tregs) among CIK cells, which suppress the antitumor activity of CIK. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b24">24</ref> Several research reports have shown that the combination of DCs and CIKs (DC-CIK) is more effective and has indicated more promising clinical prospects than single CIK treatment. <ref type="bibr" target="#b5">6</ref> In EC treatment, there are emerging data indicating CIK or DC-CIK (CIK/DC-CIK) immunotherapy in combination with conventional therapy exhibited better therapeutic efficacy than conventional therapy alone. <ref type="bibr" target="#b26">[25]</ref><ref type="bibr" target="#b27">[26]</ref><ref type="bibr" target="#b28">[27]</ref><ref type="bibr" target="#b29">[28]</ref><ref type="bibr" target="#b30">[29]</ref><ref type="bibr" target="#b31">[30]</ref><ref type="bibr" target="#b32">[31]</ref><ref type="bibr" target="#b33">[32]</ref><ref type="bibr" target="#b34">[33]</ref><ref type="bibr" target="#b35">[34]</ref><ref type="bibr" target="#b36">[35]</ref><ref type="bibr" target="#b37">[36]</ref><ref type="bibr" target="#b38">[37]</ref> However, CIK/ DC-CIK immunotherapy clinical application is still in its infancy. In this research, we conducted a meta-analysis to investigate the efficacy and safety of CIK/DC-CIK combined with conventional therapy in comparison with conventional therapy alone for EC, in order to provide scientific evidence for future clinical trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods search strategy and selection criteria</head><p>Literature reports were searched across Cochrane Library, EMBASE, PubMed, Wanfang and China National Knowledge Internet databases with the key terms "dendritic cells", "immunotherapy", "cytokine-induced killer cells" or "DC-CIK" combined with "esophageal cancer". No language limits were applied. The initial search was performed in April 2016 and updated in October 2016.</p><p>Studies selected in our research were randomized controlled clinical trials for EC. The included studies were all performed with comparison between the combination of CIK/ DC-CIK and conventional treatment (defined as combination therapy group) and conventional regimens alone (defined as conventional therapy-alone group).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data collection and quality assessment</head><p>Two authors independently searched and collected literatures from the databases according to our inclusion criteria, and they extracted the data from all the selected articles. Discrepancy was resolved by discussion with a third author. The collected information included the first authors' names, the years of publication, the numbers of subjects, patient ages, tumor stages, experiment regimens, in vitro cell culture conditions and dosages of the utilized immune cells.</p><p>The quality of the included articles was evaluated according to the Cochrane Handbook. <ref type="bibr" target="#b39">38</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition of outcome measurements</head><p>Treatment efficacy was assessed in terms of overall survival (OS), overall response rate (ORR; ORR = complete response rate + partial response rate), disease control rate (DCR; DCR = complete response rate + partial response rate + stable disease rate), patients' quality of life (QoL) and adverse events. OS was defined as the length of time from the initiation of treatment to death from any cause. <ref type="bibr" target="#b40">39</ref> The immune function of EC patients before and after treatment was determined by the status of the lymphocyte subsets (CD3 + , CD4 + , CD8 + , CD3 -CD56 + , CD3 + CD56 + and CD4 + CD25 + CD127 -) and cytokine secretion (IFN-γ, IL-2, TNF-α and IL-12).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>statistical analysis</head><p>Data were analyzed using Review Manager version 5.2 provided by Cochrane Collaboration. P,0.05 was considered statistically significant. Heterogeneity among the studies was assessed to determine the most suitable model. <ref type="bibr" target="#b41">40</ref> A randomeffects method was applied when heterogeneity existed; otherwise, a fixed-effects method was used. Cochran's Q-test was performed in order to evaluate homogeneity among studies, and I 2 ,50% or P.0.1 was considered homogeneous. Odds ratios (ORs) were the principal measurements for therapeutic effects and were presented with 95% confidence intervals (CIs).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results search results</head><p>A total of 1,405 articles were identified by initial retrieval. After title and abstract review, 1,381 articles were excluded because they did not focus on clinical trials (n=1,261), were in duplication and repetition (n=107) or were unrelated studies (n=13), and 24 studies remained as potentially relevant. After reading the full texts, 8 papers with insufficient data and 5 reviews or meta-analyses were excluded. Finally, 11 trials that included 994 EC patients met the inclusion criteria for our meta-analysis ( <ref type="figure" target="#fig_0">Figure 1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient characteristics</head><p>In all, 11 eligible trials including 994 EC patients were included in this analysis. All trials were conducted in mainland China. In total, 501 patients were treated by CIK/DC-CIK in combination with conventional therapy (combination therapy), while 493 patients were treated by conventional therapy alone. Detailed clinical information of the trials is presented in <ref type="table" target="#tab_1">Table 1</ref>. DC and CIK cells used in the 11 trials were all obtained from autologous peripheral blood. In 4 trials, DC-CIK immunotherapy was applied, whereas in the other 7 trials, only CIK cells were used. In most studies, patients were transfused with .1×10 9 immune cells, and other studies did not provide accurate cell numbers. Tumor size and injection modes were not analyzed in this article due to the lack of sufficient data in the included studies. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality assessment</head><p>The assessment for risk of bias is shown in <ref type="figure" target="#fig_3">Figure 2A</ref> and B. The quality of the involved studies ranged from moderate to high: 9 studies were low in risk of bias, while the other 2 studies did not have a clear description of the randomization process. The allocation, performance, detection and attrition risks of the involved studies were low; 3 trials were considered to be of unclear risk owing to their selective reporting, while 3 other studies were considered as high risk as they did not show primary outcome data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy assessments</head><p>This analysis indicated that OS, ORR and DCR were significantly improved in patients who underwent combination therapy compared to those treated by conventional therapy alone <ref type="figure">(Figure 3</ref>, 1-year OS: OR =2.59, 95% CI =1.52-4.40, P=0.0005; ORR: OR =2.18, 95% CI =1.57−3.02, P,0.00001; DCR: OR =3.83, 95% CI =2.47−5.92, P,0.00001). Moreover, the pooled results showed that patients in the combination therapy group had significantly improved QoL <ref type="figure">(Figure 4</ref>, QoL: OR =1.94, 95% CI =1.13−3.33, P=0.02). The fixedeffects model was applied in this analysis considering the slightly significant heterogeneity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>immune function evaluation</head><p>The immune status of patients was examined before and after the treatment. After CIK/DC-CIK treatment, the proportions of CD3 + and CD3 -CD56 + in patients were significantly increased ( <ref type="figure">Figure 5</ref>, CD3 + : OR =9.48, 95% CI =6.19−12.77, P,0.00001; CD3 -CD56 + : OR =6.57, 95% CI =2.00−11.14, P=0.005), CD4 + CD25 + CD127proportion was significantly decreased (CD4 + CD25 + CD127 -: OR =-1.72, 95% CI =-2.15 to -1.28, P,0.00001), whereas the proportions of CD4 + , CD8 + and CD3 + CD56 + and the CD4 + /CD8 + ratio did not show much differences (CD4 + : OR =2.93, 95% CI =-2. On the other hand, patients' cytokines levels were also significantly increased after CIK/DC-CIK therapy     </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>assessment of adverse events</head><p>The safety of CIK/DC-CIK therapy in the treatment of EC was evaluated in this meta-analysis. As shown in <ref type="figure" target="#fig_6">Figure 7</ref>, no serious adverse events or death occurrence was reported in the involved literature. The most common side effect was fever, which subsided naturally within 24 hours. Except the higher incidence of fever in the combination therapy group than in the conventional therapy group (fever: OR =6. <ref type="bibr" target="#b47">46</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Clinical trials have been conducted on CIK/DC-CIK immunotherapy for the treatment of EC. <ref type="bibr" target="#b27">26,</ref><ref type="bibr" target="#b32">31</ref> In this study, we performed an extensive online search, followed by rigorous meta-analysis, in order to evaluate its therapeutic efficacy and safety. Our meta-analysis revealed that the combination of CIK/DC-CIK immunotherapy and conventional therapy was a safe and effective regimen for the treatment of EC. Compared to conventional regimens alone, patients with combination therapy demonstrated higher OS rate, ORR and DCR, as well as improved immune function and QoL. This study confirmed the safety of CIK/DC-CIK immunotherapy for EC patients, and the adverse events caused were tolerated by all patients. Fever was the most common side effect when patients were treated with combination conventional-plus-CIK/DC-CIK therapy, and its incidence was higher than when treated by conventional therapy alone (P,0.05). No significant difference was observed in terms of other adverse events, such as leukopenia, gastrointestinal adverse reaction and peripheral neurotoxicity between the 2 groups (P.0.05). CIK/DC-CIK immunotherapy enhanced the efficiency of conventional therapy in the treatment of EC. Compared with the conventional therapy-alone group, 1-year OS, ORR and DCR of patients in the combination therapy group were improved remarkably (P,0.01). Moreover, the combination therapy improved patients' QoL (P,0.05) by relieving pain, reducing fatigue and insomnia as well as improving appetite.</p><p>Health status is closely related to human immune function, and a healthy human body has a robust immune system to detect and kill cancer cells. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref> However, the immune function in cancer patients is compromised, and the percentage of T-lymphocyte subsets in the peripheral blood is usually disordered. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b5">6</ref> Immune system reconstruction is one of the key factors to effectively treat malignant tumors. <ref type="bibr" target="#b5">6</ref> The antitumor activity of CIK/DC-CIK is mainly attributed to CD3 -CD56 + and CD3 + CD56 + cells. <ref type="bibr" target="#b42">41</ref> Our analysis indicated that the proportions of CD3 + , CD3 -CD56 + and CD3 + CD56 + T cells were increased after CIK/DC-CIK treatment, although the percentages of CD3 + CD56 + T cells did not reach statistical significance. However, no significant differences were found in the percentages of CD4 + , CD8 + and CD4 + /CD8 + ratios before and after immunotherapy. This may be caused by the different time points when the T-lymphocyte subsets were tested in these trials. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b19">19,</ref><ref type="bibr" target="#b43">42,</ref><ref type="bibr" target="#b44">43</ref> Our analysis revealed a decreased proportion of CD4 + CD25 + CD127 -Tregs. This is consistent with a previous study that illustrated a negative role of Tregs in the implementation of CIK's antitumor activity. <ref type="bibr" target="#b45">44</ref> Besides, the balance between the 2 helper T-cell (Th1 and Th2 cells) classes is also important in immunotherapy. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b42">41</ref> Th1 cells enhance killer cells' cytotoxicity and trigger delayed-type hypersensitivity, whereas Th2 cells are associated with tumor immune escape. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b46">45</ref> Our analysis showed that after CIK/DC-CIK immunotherapy, the levels of Th1 cytokines, including IFN-γ, IL-2, TNF-α and IL-12, were significantly increased (P,0.00001), indicating a strong association between Th1 cytokines and efficacy of CIK/DC-CIK immunotherapy. Although our results indicated that CIK/DC-CIK immunotherapy enhanced the immune function in EC patients, the exact underlying mechanism of action of CIK/DC-CIK immunotherapy on hosts' immune system remains unclear, which requires further studies on its mechanism.</p><p>This meta-analysis has some limitations. First of all, although CIK/DC-CIK immunotherapy has been applied to treat malignancies worldwide for its outstanding curative effects, <ref type="bibr" target="#b47">[46]</ref><ref type="bibr" target="#b48">[47]</ref><ref type="bibr" target="#b49">[48]</ref> all of the clinic trials that met our inclusion criteria were carried out in the Chinese population. We will follow updated publications on CIK/DC-CIK immunotherapy for EC conducted both in China and other countries and subsequently perform further systematic research on it. Moreover, the analysis performed in this study was not subjected to an open external evaluation procedure, which may lead to an overestimation of treatment effects. In addition, insufficient information regarding some patients, small sample sizes and other variables may have introduced bias into our conclusions. Besides, the clinical application of adoptive CIK/ DC-CIK immunotherapy was limited due to the low specificity, although it is a promising strategy for the treatment of malignant tumors. Many new methods of immunotherapy, such as chimeric antigen receptor-modified T cells and T-cell receptor-modified T cells, have been developed currently, <ref type="bibr" target="#b50">[49]</ref><ref type="bibr" target="#b51">[50]</ref><ref type="bibr" target="#b52">[51]</ref> limiting the importance of this study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>Taken together, this meta-analysis suggests that the combination of CIK/DC-CIK immunotherapy and conventional regimens is safe and effective in treating patients with EC, with markedly prolonged survival time, enhanced immune function and improved therapeutic efficacy. Considering the limitations of our research, further analysis on studies conducted in countries other than China with larger sample sizes and going through open external evaluation procedure will be valuable to verify the credibility of our conclusions.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc>Flow diagram of the selection process.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>42 to 8.29, P=0.28; CD8 + : OR =2.00, 95% CI =-4.11 to 8.11, P=0.52; CD4 + /CD8 + : OR =-0.01, 95% CI =-0.53 to 0.51, P=0.97; CD3 + CD56 + : OR =6.24, 95% CI =-2.48 to 14.97, P=0.16).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Notes:</head><label></label><figDesc>The table summarizes patients' basic information regarding the tumor stage, treatment regimens, cases, age and details of the immunotherapy (culture conditions, cell doses and the treatment courses). a Dcs cultivated with ciK before injection; b coinjection of Dcs with ciKs. Abbreviations: cD, cluster of differentiation; ciK, cytokine-induced killer cell; cM, chinese medicine (huisheng oral liquid); con, control group; cT, chemotherapy; Dc, dendritic cell; exp, experimental group; gM-csF, granulocyte-macrophage colony-stimulating factor; iFn, interferon; il, interleukin; OKT-3, cD3 monoclonal antibodies; nD, not determined; rT, radiotherapy; TnF, tumor necrosis factor.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2</head><label>2</label><figDesc>review of authors' judgments about each risk of bias item for included studies. Notes: (A) risk of bias summary. (B) risk of bias graph: review of authors' judgments about each risk of bias item presented as percentages across all included studies.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3 Figure 4</head><label>34</label><figDesc>Forest plot for the comparison of Qir. Note: The fixed-effects meta-analysis model (Mantel-Haenszel method) was used. Abbreviations: CI, confidence interval; CIK/DC-CIK, immunotherapy with cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells; cont, conventional therapy; M-h, Mantel-haenszel method; Qir, quality-of-life improved rate.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 3 Figure 5 Figure 6</head><label>356</label><figDesc>Forest plots of the comparisons of (A) Os and (B) Orr and Dcr. Note: The fixed-effects meta-analysis model (Mantel-Haenszel method) was used. Abbreviations: CI, confidence interval; CIK/DC-CIK, immunotherapy with cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells; cont, conventional therapy; Dcr, disease control rate; M-h, Mantel-haenszel method; Orr, overall response rate; Os, overall survival. Forest plot of immunophenotype assessment before and after treatment with ciK/Dc-ciK.Note: The random-effects meta-analysis model (Mantel-haenszel method) was used in this analysis.Abbreviations: CD, cluster of differentiation; CI, confidence interval; CIK/DC-CIK, immunotherapy with cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells; sD, standard deviation. Forest plot of cytokines before and after treatment with ciK/Dc-ciK. Note: The fixed-effects meta-analysis model (Mantel-Haenszel method) was used in this analysis. Abbreviations: CI, confidence interval; CIK/DC-CIK, immunotherapy with cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells; iFn, interferon; il, interleukin; sD, standard deviation; TnF, tumor necrosis factor. (Figure 6, IFN-γ: OR =36.30, 95% CI =31.54−41.06, P,0.00001; IL-2: OR =13.00, 95% CI =9.88−16.12, P,0.00001; TNF-α: OR =15.10, 95% CI =12.31−17.89, P,0.00001; IL-12: OR =56.30, 95% CI =51.32−61.28, P,0.00001).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 7</head><label>7</label><figDesc>Forest plot of the comparison of adverse effects. Note: The random-effects meta-analysis model (Mantel-haenszel method) was used in this analysis. Abbreviations: CI, confidence interval; CIK/DC-CIK, immunotherapy with cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells; cont, conventional therapy; M-h, Mantel-haenszel method.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc>clinical information from the eligible trials used in the meta-analysis</figDesc><table><row><cell>Authors</cell><cell cols="2">Year Stage Exp</cell><cell>Patients, Con/</cell><cell>Age, years</cell><cell></cell><cell>Culture</cell><cell>Cell dose (cycles)</cell></row><row><cell></cell><cell></cell><cell>regimens</cell><cell>Exp groups</cell><cell>Con</cell><cell>Exp</cell><cell>conditions</cell><cell></cell></row><row><cell>chang et al 28</cell><cell>2013 iii-iV</cell><cell>cT, ciK</cell><cell>33/33</cell><cell>66 (median)</cell><cell>66 (median)</cell><cell cols="2">iFn-γ, il-2, OKT-3 1×10 9 /cycle (2 cycles)</cell></row><row><cell>hu 29</cell><cell>2012 iii-iV</cell><cell cols="2">cM, cT, ciK 25/37</cell><cell>nD</cell><cell>nD</cell><cell>iFn-γ, il-1, il-2</cell><cell>.1×10 9 /cycle (nD)</cell></row><row><cell>liu et al 30</cell><cell>2011 iii-iV</cell><cell>cT, ciK</cell><cell>20/20</cell><cell>62 (median)</cell><cell>62 (median)</cell><cell cols="2">iFn-γ, il-2, OKT-3 (0.6-1.6)×10 10 /cycle</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(3 cycles)</cell></row><row><cell>Qu et al 31</cell><cell>2015 iV</cell><cell>cT, ciK</cell><cell>100/100</cell><cell cols="3">56.3±7.5 (mean) 56.3±7.5 (mean) iFn-γ, OKT-3,</cell><cell>nD (nD)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>il-2, il-12</cell><cell></cell></row><row><cell>shu et al 32</cell><cell>2015 ii-iii</cell><cell cols="2">rT, cT, ciK 30/30</cell><cell>59 (median)</cell><cell>57 (median)</cell><cell cols="2">iFn-γ, OKT-3, il-2 5×10 10 /cycle (nD)</cell></row><row><cell cols="2">Wang et al 33,41 2014 i-iV</cell><cell cols="2">cT, Dc-ciK a 62/62</cell><cell>nD</cell><cell>nD</cell><cell>iFn-γ, il-2, OKT-3</cell><cell>2×10 10 /cycle (nD)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(ciK)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>gM-csF, il-4,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>iFn-γ (Dc)</cell><cell></cell></row><row><cell>Xi et al 34</cell><cell cols="2">2015 ii-iiiB surgery, cT,</cell><cell>26/26</cell><cell>62 (median)</cell><cell>60 (median)</cell><cell>iFn-γ, il-1, il-2,</cell><cell>3-4×10 9 /cycle</cell></row><row><cell></cell><cell></cell><cell>Dc-ciK a</cell><cell></cell><cell></cell><cell></cell><cell>OKT-3 (ciK)</cell><cell>(2 cycles)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>gM-csF, il-4,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>TnF-α, il-1 (Dc)</cell><cell></cell></row><row><cell>Xu et al 35</cell><cell>2010 iii-iV</cell><cell>cT, ciK</cell><cell>25/21</cell><cell>42 (mean)</cell><cell>45 (mean)</cell><cell>iFn-γ, il-1α, il-2,</cell><cell>.5×10 9 /cycle</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>OKT-3</cell><cell>(4 cycles)</cell></row><row><cell>Yan et al 26</cell><cell>2015 i-iV</cell><cell cols="2">rT, Dc-ciK b 34/34</cell><cell cols="3">71.6±2.2 (mean) 70.5±2.9 (mean) iFn-γ, il-1α, il-2,</cell><cell>5×10 9 /cycle (ciK)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>OKT-3 (ciK)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>gM-csF, il-4</cell><cell>5×10 7 /cycle (Dc)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Dc)</cell><cell>(nD)</cell></row><row><cell>Yang et al 36</cell><cell>2015 nD</cell><cell cols="2">cT, Dc-ciK a 100/100</cell><cell cols="3">72.3±6.9 (mean) 70.2±7.3 (mean) nD</cell><cell>nD (1-2 cycles)</cell></row><row><cell>Zhu and</cell><cell>2014 nD</cell><cell>cT, ciK</cell><cell>38/38</cell><cell cols="3">59.8±1.4 (mean) 59.6±1.3 (mean) nD</cell><cell>nD (nD)</cell></row><row><cell>Zhang 37</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>,</head><label></label><figDesc>95% CI =2.42-17.21, P=0.0002), no significant difference was observed in terms of leukopenia, gastrointestinal adverse reaction and peripheral neurotoxicity (leukopenia: OR =0.91, 95% CI =0.39-2.12, P=0.83; gastrointestinal adverse reaction: OR =0.51, 95% CI =0.22-1.22, P=0.13; peripheral neurotoxicity: OR =0.75, 95% CI =0.26-2.15, P=0.59).</figDesc><table /><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">submit your manuscript | www.dovepress.com Dovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.comDovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.comDovepressDovepressDovepress</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgment</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head><p>Changhui Zhou and Yingxin Zhang conceived and designed the experiments. Yan Liu, Ying Mu and Shaoda Ren performed the experiments. Weihua Wang and Jiaping Xie analyzed the data. Yan Liu and Ying Mu drafted the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p>The authors report no conflicts of interest in this work.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OncoTargets and Therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publish your work in this journal</head><p>Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Minimally invasive esophagectomy versus open esophagectomy for esophageal cancer: a meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lu</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weidong</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanchen</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaoxuan</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.2147/ott.s112105</idno>
		<idno type="PMID">27826201</idno>
		<idno type="PMCID">PMC5096744</idno>
		<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=33300" />
	</analytic>
	<monogr>
		<title level="j">OncoTargets and Therapy</title>
		<title level="j" type="abbrev">OTT</title>
		<idno type="ISSNe">1178-6930</idno>
		<imprint>
			<biblScope unit="volume">Volume 9</biblScope>
			<biblScope unit="page" from="6751" to="6762" />
			<date type="published" when="2016-10" />
			<publisher>Dove Medical Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prognostic gene expression profiling in esophageal cancer: a systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Els</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ingrid</forename><forename type="middle">A</forename><surname>Franken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lodewijk</forename><forename type="middle">A A</forename><surname>Brosens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jelle</forename><forename type="middle">P</forename><surname>Ruurda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><surname>Van Hillegersberg</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.13328</idno>
		<idno type="PMID">27852047</idno>
		<idno type="PMCID">PMC5354930</idno>
		<ptr type="open-access" target="http://www.oncotarget.com/index.php?journal=oncotarget&amp;page=article&amp;op=download&amp;path%5B%5D=13328&amp;path%5B%5D=42305" />
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<title level="j" type="abbrev">Oncotarget</title>
		<idno type="ISSNe">1949-2553</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="5566" to="5577" />
			<date type="published" when="2016-11-12" />
			<publisher>Impact Journals, LLC</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Role of endoscopy in early oesophageal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jayan</forename><surname>Mannath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Krish</forename><surname>Ragunath</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrgastro.2016.148</idno>
		<idno type="PMID">27807370</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Gastroenterology &amp; Hepatology</title>
		<title level="j" type="abbrev">Nat Rev Gastroenterol Hepatol</title>
		<idno type="ISSN">1759-5045</idno>
		<idno type="ISSNe">1759-5053</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="720" to="730" />
			<date type="published" when="2016-11-03" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Immunotherapy for Gastroesophageal Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emily</forename><surname>Goode</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><surname>Smyth</surname></persName>
		</author>
		<idno type="DOI">10.3390/jcm5100084</idno>
		<idno type="PMID">27669318</idno>
		<idno type="PMCID">PMC5086586</idno>
		<ptr type="open-access" target="https://www.mdpi.com/2077-0383/5/10/84/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Medicine</title>
		<title level="j" type="abbrev">JCM</title>
		<idno type="ISSNe">2077-0383</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">84</biblScope>
			<date type="published" when="2016-09-22" />
			<publisher>MDPI AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell–cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang-Hui</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shuang-Feng</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying-Xin</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ya-Pei</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Hua</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcyt.2016.05.015</idno>
		<idno type="PMID">27421742</idno>
	</analytic>
	<monogr>
		<title level="j">Cytotherapy</title>
		<title level="j" type="abbrev">Cytotherapy</title>
		<idno type="ISSN">1465-3249</idno>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1162" to="1177" />
			<date type="published" when="2016-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cuiling</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donglan</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huanhuan</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaobin</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shuncong</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guobin</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Saradhi</forename><surname>Mallampati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hongliu</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiuling</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhibin</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hongyu</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haiqing</forename><surname>Ma</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.13394</idno>
		<idno type="PMID">27863436</idno>
		<idno type="PMCID">PMC5349930</idno>
		<ptr type="open-access" target="http://www.oncotarget.com/index.php?journal=oncotarget&amp;page=article&amp;op=download&amp;path%5B%5D=13394&amp;path%5B%5D=42506" />
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<title level="j" type="abbrev">Oncotarget</title>
		<idno type="ISSNe">1949-2553</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">52</biblScope>
			<biblScope unit="page" from="86500" to="86510" />
			<date type="published" when="2016-11-16" />
			<publisher>Impact Journals, LLC</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongfeng</forename><surname>Si</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhuoxia</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guiping</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haijun</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongli</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jinyuan</forename><surname>Si</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiazhang</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingjin</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yangda</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bo</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying</forename><surname>Qin</surname></persName>
		</author>
		<idno type="DOI">10.1248/cpb.c16-00114</idno>
		<idno type="PMID">27477649</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/cpb/64/8/64_c16-00114/_pdf" />
	</analytic>
	<monogr>
		<title level="j">Chemical and Pharmaceutical Bulletin</title>
		<title level="j" type="abbrev">CHEMICAL &amp; PHARMACEUTICAL BULLETIN</title>
		<idno type="ISSN">0009-2363</idno>
		<idno type="ISSNe">1347-5223</idno>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1118" to="1123" />
			<date type="published" when="2016" />
			<publisher>Pharmaceutical Society of Japan</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Passalacqua</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Caminiti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Buti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="440" to="447" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: A meta-analysis.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tengfei</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruitai</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ni</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wang</forename><surname>Ma</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2017.35.15_suppl.e23075</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc5341964?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<title level="j" type="abbrev">JCO</title>
		<idno type="ISSN">0732-183X</idno>
		<idno type="ISSNe">1527-7755</idno>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">15_suppl</biblScope>
			<biblScope unit="page" from="e23075" to="e23075" />
			<date type="published" when="2017-05-20" />
			<publisher>American Society of Clinical Oncology (ASCO)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">S</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sandra</forename><forename type="middle">P</forename><surname>D'angelo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Minor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">Stephen</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralf</forename><surname>Gutzmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bart</forename><surname>Neyns</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christoph</forename><surname>Hoeller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nikhil</forename><forename type="middle">I</forename><surname>Khushalani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wilson</forename><forename type="middle">H</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">D</forename><surname>Lao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gerald</forename><forename type="middle">P</forename><surname>Linette</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luc</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><surname>Lorigan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><forename type="middle">F</forename><surname>Grossmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jessica</forename><forename type="middle">C</forename><surname>Hassel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michele</forename><surname>Maio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mario</forename><surname>Sznol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paolo</forename><forename type="middle">A</forename><surname>Ascierto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Mohr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bartosz</forename><surname>Chmielowski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><surname>Bryce</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Inge</forename><forename type="middle">M</forename><surname>Svane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Jacques</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angela</forename><forename type="middle">M</forename><surname>Krackhardt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><surname>Horak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexandre</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arvin</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><surname>Larkin</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1470-2045(15)70076-8</idno>
		<idno type="PMID">25795410</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Oncology</title>
		<title level="j" type="abbrev">The Lancet Oncology</title>
		<idno type="ISSN">1470-2045</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="375" to="384" />
			<date type="published" when="2015-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shukui</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianming</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianping</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Changping</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuxian</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiandong</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yunpeng</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruihua</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhehai</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qiong</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xuenong</forename><surname>Ouyang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><surname>Ba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaoyan</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deyun</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rongsheng</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xin</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guoping</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liwei</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leizhen</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingbo</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nong</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianwei</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Honggang</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ningju</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lei</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhining</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Piaoyang</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hao</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2015.63.5995</idno>
		<idno type="PMID">26884585</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<title level="j" type="abbrev">JCO</title>
		<idno type="ISSN">0732-183X</idno>
		<idno type="ISSNe">1527-7755</idno>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1448" to="1454" />
			<date type="published" when="2016-05" />
			<publisher>American Society of Clinical Oncology (ASCO)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Boye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xin</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vichien</forename><surname>Srimuninnimit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><forename type="middle">Hyoung</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun-Ming</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mauro</forename><surname>Orlando</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tarun</forename><surname>Puri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><forename type="middle">Seok</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Narayan</forename><surname>Rajan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James Chih-Hsin</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cllc.2015.12.004</idno>
		<idno type="PMID">26809984</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Lung Cancer</title>
		<title level="j" type="abbrev">Clinical Lung Cancer</title>
		<idno type="ISSN">1525-7304</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="150" to="160" />
			<date type="published" when="2016-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Development of new immunotherapy treatments in different cancer types</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Stanculeanu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Daniela</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lazescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bunghez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Anghel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Life</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="240" to="248" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">E</forename><surname>Peoples</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><forename type="middle">M</forename><surname>Gurney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">T</forename><surname>Hueman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mike</forename><forename type="middle">M</forename><surname>Woll</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gayle</forename><forename type="middle">B</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Catherine</forename><forename type="middle">E</forename><surname>Storrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Craig</forename><forename type="middle">D</forename><surname>Shriver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Constantin</forename><forename type="middle">G</forename><surname>Ioannides</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sathibalan</forename><surname>Ponniah</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2005.03.047</idno>
		<idno type="PMID">16157940</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<title level="j" type="abbrev">JCO</title>
		<idno type="ISSN">0732-183X</idno>
		<idno type="ISSNe">1527-7755</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="7536" to="7545" />
			<date type="published" when="2005-10-20" />
			<publisher>American Society of Clinical Oncology (ASCO)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">E</forename><surname>Dudley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><forename type="middle">A</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">P T</forename><surname>Somerville</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicholas</forename><forename type="middle">P</forename><surname>Schaub</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shannon</forename><forename type="middle">F</forename><surname>Rosati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donald</forename><forename type="middle">E</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Debbie</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicholas</forename><forename type="middle">P</forename><surname>Restifo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seth</forename><forename type="middle">M</forename><surname>Steinberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">R</forename><surname>Wunderlich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Udai</forename><forename type="middle">S</forename><surname>Kammula</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">M</forename><surname>Sherry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giao</forename><forename type="middle">Q</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marybeth</forename><forename type="middle">S</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carolyn</forename><forename type="middle">M</forename><surname>Laurencot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">A</forename><surname>Rosenberg</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2012.46.6441</idno>
		<idno type="PMID">23650429</idno>
		<idno type="PMCID">PMC3731980</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3731980?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<title level="j" type="abbrev">JCO</title>
		<idno type="ISSN">0732-183X</idno>
		<idno type="ISSNe">1527-7755</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2152" to="2159" />
			<date type="published" when="2013-06-10" />
			<publisher>American Society of Clinical Oncology (ASCO)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">cytokine-induced killer cells for the treatment of esophageal cancer</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced nonsmall-cell lung cancer treated with concomitant radiochemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Ju</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Tradit Chin Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="14" to="18" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Whay-Kuang</forename><surname>Chia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marissa</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Who-Whong</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernett</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soo-Fan</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wai-Meng</forename><surname>Tai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chit-Lai</forename><surname>Chee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joanna</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rebecca</forename><surname>Kan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wan-Teck</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sze-Huey</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Whee-Sze</forename><surname>Ong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yin-Bun</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eng-Huat</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">E</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><surname>Gottschalk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Han-Chong</forename><surname>Toh</surname></persName>
		</author>
		<idno type="DOI">10.1038/mt.2013.242</idno>
		<idno type="PMID">24297049</idno>
		<idno type="PMCID">PMC3978790</idno>
		<ptr type="open-access" target="http://www.cell.com/article/S1525001616311273/pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Therapy</title>
		<title level="j" type="abbrev">Molecular Therapy</title>
		<idno type="ISSN">1525-0016</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="132" to="139" />
			<date type="published" when="2014-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Clara</forename><forename type="middle">E</forename><surname>Jäkel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Annabelle</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">A</forename><surname>Gonzalez-Carmona</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ingo</forename><forename type="middle">G H</forename><surname>Schmidt-Wolf</surname></persName>
		</author>
		<idno type="DOI">10.1155/2014/897214</idno>
		<idno type="PMID">24741629</idno>
		<idno type="PMCID">PMC3987941</idno>
		<ptr type="open-access" target="http://downloads.hindawi.com/journals/jir/2014/897214.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Immunology Research</title>
		<title level="j" type="abbrev">Journal of Immunology Research</title>
		<idno type="ISSN">2314-8861</idno>
		<idno type="ISSNe">2314-7156</idno>
		<imprint>
			<biblScope unit="volume">2014</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2014" />
			<publisher>Hindawi Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liangrong</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qi</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mei</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guojun</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingting</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Changping</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00262-012-1289-2</idno>
		<idno type="PMID">22674056</idno>
		<idno type="PMCID">PMC3506195</idno>
		<idno type="ark">ark:/67375/VQC-4RF3DR8L-C</idno>
		<idno type="istexId">6442E3F807B302B69C72050DAE40E45F78F92DC5</idno>
		<ptr type="open-access" target="https://link.springer.com/content/pdf/10.1007%2Fs00262-012-1289-2.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Immunology, Immunotherapy</title>
		<title level="j" type="abbrev">Cancer Immunol Immunother</title>
		<idno type="ISSN">0340-7004</idno>
		<idno type="ISSNe">1432-0851</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2251" to="2259" />
			<date type="published" when="2012-06-07" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Comparison of the proliferation, cytotoxic activity and cytokine secretion function of cascade primed immune cells and cytokine-induced killer cells in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gui-Xin</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shu-Shu</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xu-Guang</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen-Hao</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ke-Wei</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Yan</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying-Xue</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li-Hua</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3892/mmr.2015.3765</idno>
		<idno type="PMID">25955083</idno>
		<idno type="PMCID">PMC4464195</idno>
		<ptr type="open-access" target="http://www.spandidos-publications.com/10.3892/mmr.2015.3765/download" />
	</analytic>
	<monogr>
		<title level="j">Molecular Medicine Reports</title>
		<idno type="ISSN">1791-2997</idno>
		<idno type="ISSNe">1791-3004</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2629" to="2635" />
			<date type="published" when="2015-05-08" />
			<publisher>Spandidos Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">A</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">G</forename><surname>Schmidt-Wolf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">L</forename><surname>Weissman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Negrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3493" to="3499" />
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanjuan</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haibo</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianping</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lirong</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yihong</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanchun</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xin</forename><surname>Qu</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00262-013-1465-z</idno>
		<idno type="PMID">23974720</idno>
		<idno type="ark">ark:/67375/VQC-5KQ50SJK-H</idno>
		<idno type="istexId">23A68D623075CB75358DDA473961244EC2B2CE72</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunology, Immunotherapy</title>
		<title level="j" type="abbrev">Cancer Immunol Immunother</title>
		<idno type="ISSN">0340-7004</idno>
		<idno type="ISSNe">1432-0851</idno>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1629" to="1635" />
			<date type="published" when="2013-08-23" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">C</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">R</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="19725" to="19730" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">树突状细胞对CIK细 胞中CD4+CD25+ T细胞数量及免疫调节作用的影响 [Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">B</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">M</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">S</forename><surname>Hao</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>duced killer cells</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Yi Xue Za Zhi</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">44</biblScope>
			<biblScope unit="page" from="3134" to="3138" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daiqing</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Changyou</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xihe</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peng</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiaofang</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weihong</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hsin-Chen</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aris</forename><forename type="middle">T</forename><surname>Alexandrou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronghua</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><forename type="middle">Jian</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0093886</idno>
		<idno type="PMID">24699863</idno>
		<idno type="PMCID">PMC3974849</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093886&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">e93886</biblScope>
			<date type="published" when="2014-04-03" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Ba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">Y</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.4238/2015.february.2.13</idno>
		<idno type="PMID">25730028</idno>
		<ptr type="open-access" target="https://doi.org/10.4238/2015.february.2.13" />
	</analytic>
	<monogr>
		<title level="j">Genetics and Molecular Research</title>
		<title level="j" type="abbrev">Genet. Mol. Res.</title>
		<idno type="ISSNe">1676-5680</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="898" to="905" />
			<date type="published" when="2015" />
			<publisher>Genetics and Molecular Research</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Efficacy and safety of cord blood–derived cytokine-induced killer cells in treatment of patients with malignancies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhen</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liping</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhenzhen</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xuan</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianmin</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shuangning</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xianlan</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lei</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liuxia</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lan</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcyt.2015.04.002</idno>
		<idno type="PMID">25963952</idno>
	</analytic>
	<monogr>
		<title level="j">Cytotherapy</title>
		<title level="j" type="abbrev">Cytotherapy</title>
		<idno type="ISSN">1465-3249</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1130" to="1138" />
			<date type="published" when="2015-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinical observation of cytokine induced killer cell intravenous transfusion combined with chemotherapy in treatment of advanced esophageal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">G</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Shandong Med J</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="53" to="54" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Effect of herb plus adoptive immunotherapy with cytokine induced killer cells on cellular immunity of patients with advanced esophageal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">Q</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bengbu Med Coll</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1062" to="1066" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yaomei</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">B</forename><surname>Kellner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lingdi</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Linping</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Quanli</forename><surname>Gao</surname></persName>
		</author>
		<idno type="DOI">10.3892/ol.2016.4629</idno>
		<idno type="PMID">27347204</idno>
		<idno type="PMCID">PMC4907280</idno>
		<ptr type="open-access" target="http://www.spandidos-publications.com/10.3892/ol.2016.4629/download" />
	</analytic>
	<monogr>
		<title level="j">Oncology Letters</title>
		<idno type="ISSN">1792-1074</idno>
		<idno type="ISSNe">1792-1082</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="707" to="714" />
			<date type="published" when="2016-05-25" />
			<publisher>Spandidos Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">IL-12 induced CIK cells combined with chemotherapy improve immune function and efficacy in patients with esophageal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Feng</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Min</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Yun</forename><surname>Ding</surname></persName>
		</author>
		<idno type="DOI">10.11569/wcjd.v23.i28.4553</idno>
	</analytic>
	<monogr>
		<title level="j">World Chinese Journal of Digestology</title>
		<title level="j" type="abbrev">WCJD</title>
		<idno type="ISSN">2219-2859</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">28</biblScope>
			<biblScope unit="page">4553</biblScope>
			<date type="published" when="2015" />
			<publisher>Baishideng Publishing Group Inc.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Autologous cytokineinduced killer cells combined with chemoradiation in the treatment of locally advanced esophageal carcinoma: a randomized control study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Gan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1376" to="1380" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Effect of dendritic cellcytokine-induced killer cell adoptive immunotherapy combined with chemotherapy on T cell subsets of patients with esophageal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">H</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">L</forename><surname>Shi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Contemp Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">28</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Effect of DC-CIK cells&apos; biotherapy in comprehensive therapy of esophagus cancer: a randomized controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">X</forename><surname>Xi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">H</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Clin Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="765" to="769" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Clinical effects on chemotherapy combined with CIK for patients with advanced oesophageal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">L</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Henan Med Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="315" to="320" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The clinical efficacy of endoscopic implantation with chemotherapeutic slow-release combined with DC-CIK immune cells infusion for patients with obstructive esophageal cancers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">A</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">China J Endoscopy</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="483" to="486" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Analysis of the effect of injection in treatment of advanced esophageal cancer paclitaxel cisplatin regimen combined with autologous CIK cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">P</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">A</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Clin Oncol Rehabil</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="837" to="839" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiantao</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yonggang</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joey</forename><forename type="middle">S W</forename><surname>Kwong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chao</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sheng</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuming</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liang</forename><surname>Du</surname></persName>
		</author>
		<idno type="DOI">10.1111/jebm.12141</idno>
		<idno type="PMID">25594108</idno>
		<idno type="ark">ark:/67375/WNG-2RN1XX4G-6</idno>
		<idno type="istexId">5A9FE4ED65347A2FB5C868DBB14361FCCB5607C0</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Evidence-Based Medicine</title>
		<title level="j" type="abbrev">Journal of Evidence-Based Medicine</title>
		<idno type="ISSN">1756-5383</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="2" to="10" />
			<date type="published" when="2015-02" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Effectiveness and Safety of Chemotherapy Combined with Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cells in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rui-Xian</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xu</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pan</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying-Jie</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Chun</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0108958</idno>
		<idno type="PMID">25268709</idno>
		<idno type="PMCID">PMC4182599</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0108958&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">e108958</biblScope>
			<date type="published" when="2014-09-30" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Quantifying the impact of between-study heterogeneity in multivariate meta-analyses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dan</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ian</forename><forename type="middle">R</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">D</forename><surname>Riley</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.5453</idno>
		<idno type="PMID">22763950</idno>
		<idno type="PMCID">PMC3546377</idno>
		<idno type="ark">ark:/67375/WNG-RKHWRS7V-X</idno>
		<idno type="istexId">9F605F54CE4663C0B898B3B55A03551AF48615E0</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3546377?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Statistics in Medicine</title>
		<title level="j" type="abbrev">Statist. Med.</title>
		<idno type="ISSN">0277-6715</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">29</biblScope>
			<biblScope unit="page" from="3805" to="3820" />
			<date type="published" when="2012-07-04" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zheng-Xu</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun-Xia</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duo</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu-Xin</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Yan</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Long</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun-Li</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcyt.2014.02.011</idno>
		<idno type="PMID">24794183</idno>
	</analytic>
	<monogr>
		<title level="j">Cytotherapy</title>
		<title level="j" type="abbrev">Cytotherapy</title>
		<idno type="ISSN">1465-3249</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="934" to="945" />
			<date type="published" when="2014-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vida</forename><surname>Milašienė</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eugenijus</forename><surname>Stratilatovas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Violeta</forename><surname>Norkienė</surname></persName>
		</author>
		<idno type="DOI">10.3390/medicina43070069</idno>
		<ptr type="open-access" target="http://www.mdpi.com/1010-660X/43/7/548/pdf" />
	</analytic>
	<monogr>
		<title level="j">Medicina</title>
		<title level="j" type="abbrev">Medicina</title>
		<idno type="ISSNe">1010-660X</idno>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">548</biblScope>
			<date type="published" when="2007-05-23" />
			<publisher>MDPI AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">T-Lymphocyte Subsets in Patients with AJCC Stage III Gastric Cancer during Postoperative Adjuvant Chemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Y</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">G</forename><surname>Joh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">R</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">I</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">H</forename><surname>Koo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Whang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">O</forename><surname>Suh</surname></persName>
		</author>
		<idno type="DOI">10.1177/145749690209100207</idno>
		<idno type="PMID">12164518</idno>
		<ptr type="open-access" target="https://journals.sagepub.com/doi/pdf/10.1177/145749690209100207" />
	</analytic>
	<monogr>
		<title level="j">Scandinavian Journal of Surgery</title>
		<title level="j" type="abbrev">Scand J Surg</title>
		<idno type="ISSN">1457-4969</idno>
		<idno type="ISSNe">1799-7267</idno>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="172" to="177" />
			<date type="published" when="2002-06" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Targeting regulatory T cells in cytokine-induced killer cell cultures (Review)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qianshan</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huiping</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhimin</forename><surname>Zhai</surname></persName>
		</author>
		<idno type="DOI">10.3892/br.2014.234</idno>
		<idno type="PMID">24748966</idno>
		<idno type="PMCID">PMC3990197</idno>
		<ptr type="open-access" target="http://www.spandidos-publications.com/br/2/3/317/download" />
	</analytic>
	<monogr>
		<title level="j">Biomedical Reports</title>
		<idno type="ISSN">2049-9434</idno>
		<idno type="ISSNe">2049-9442</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="317" to="320" />
			<date type="published" when="2014-02-07" />
			<publisher>Spandidos Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">P</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Onco Targets Ther</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="4617" to="4627" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Olioso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffaella</forename><surname>Giancola</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><surname>Di Riti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessandro</forename><surname>Contento</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrizia</forename><surname>Accorsi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Antonio</forename><surname>Iacone</surname></persName>
		</author>
		<idno type="DOI">10.1002/hon.886</idno>
		<idno type="PMID">19294626</idno>
		<idno type="ark">ark:/67375/WNG-XK9XF7GT-B</idno>
		<idno type="istexId">7E5FF510F7B96BCE44EAF17BE64E9CD7DFB8E1C3</idno>
	</analytic>
	<monogr>
		<title level="j">Hematological Oncology</title>
		<title level="j" type="abbrev">Hematol. Oncol.</title>
		<idno type="ISSN">0278-0232</idno>
		<idno type="ISSNe">1099-1069</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="130" to="139" />
			<date type="published" when="2009-09" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joon</forename><forename type="middle">Hyeok</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeong-Hoon</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Suk</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><forename type="middle">Eun</forename><surname>Yeon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae-Jin</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Su</forename><forename type="middle">Jong</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geum-Youn</forename><surname>Gwak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kang</forename><forename type="middle">Mo</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoon</forename><forename type="middle">Jun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae</forename><forename type="middle">Won</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jung-Hwan</forename><surname>Yoon</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2015.02.055</idno>
		<idno type="PMID">25747273</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<title level="j" type="abbrev">Gastroenterology</title>
		<idno type="ISSN">0016-5085</idno>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1383" to="1391.e6" />
			<date type="published" when="2015-06" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note>e6</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Feasibility and Safety of Adoptive Immunotherapy with CIK Cells after Cord Blood Transplantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martino</forename><surname>Introna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alice</forename><surname>Pievani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gianmaria</forename><surname>Borleri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chiara</forename><surname>Capelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessandra</forename><surname>Algarotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caterina</forename><surname>Micò</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Grassi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elena</forename><surname>Oldani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Josée</forename><surname>Golay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessandro</forename><surname>Rambaldi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbmt.2010.05.015</idno>
		<idno type="PMID">20685246</idno>
	</analytic>
	<monogr>
		<title level="j">Biology of Blood and Marrow Transplantation</title>
		<title level="j" type="abbrev">Biology of Blood and Marrow Transplantation</title>
		<idno type="ISSN">1083-8791</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1603" to="1607" />
			<date type="published" when="2010-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yue</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zan</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lei</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying-Chun</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhi-Ming</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Feng</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong-Xia</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3109/14653249.2011.649185</idno>
		<idno type="PMID">22277010</idno>
	</analytic>
	<monogr>
		<title level="j">Cytotherapy</title>
		<title level="j" type="abbrev">Cytotherapy</title>
		<idno type="ISSN">1465-3249</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="483" to="493" />
			<date type="published" when="2012-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tengfei</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ling</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jing</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ni</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhen</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhenzhen</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dongli</forename><surname>Yue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zimeng</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liping</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weidong</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhongwei</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hu</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.5582</idno>
		<idno type="PMID">26376680</idno>
		<idno type="PMCID">PMC4741817</idno>
		<ptr type="open-access" target="http://www.oncotarget.com/index.php?journal=oncotarget&amp;page=article&amp;op=download&amp;path%5B%5D=5582&amp;path%5B%5D=13114" />
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<title level="j" type="abbrev">Oncotarget</title>
		<idno type="ISSNe">1949-2553</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">32</biblScope>
			<biblScope unit="page" from="33961" to="33971" />
			<date type="published" when="2015-09-11" />
			<publisher>Impact Journals, LLC</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">C</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Burga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Mccormack</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Mooring</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">R</forename><surname>Point</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">D</forename><surname>Khare</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Thorn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">F</forename><surname>Stainken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">O</forename><surname>Assanah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">J</forename><surname>Espat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">P</forename><surname>Junghans</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.ccr-14-1421</idno>
		<idno type="PMID">25850950</idno>
		<idno type="PMCID">PMC4506253</idno>
		<ptr type="open-access" target="https://clincancerres.aacrjournals.org/content/clincanres/21/14/3149.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<title level="j" type="abbrev">Clinical Cancer Research</title>
		<idno type="ISSN">1078-0432</idno>
		<idno type="ISSNe">1557-3265</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="3149" to="3159" />
			<date type="published" when="2015-04-07" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
